The drug TroVax will be studied as a treatment for malignant mesothelioma by a partnership between a major biopharmaceutical company in the UK and researchers at Cardiff University in Wales.

The news website RTT News reported that Oxford BioMedica will team up with cancer immunologists led by Zsuzsanna Tabi at Cardiff University and oncologist Dr. Jason Lester of Velindre Cancer Center in Cardiff.

In the study, the drug will be used in combination with first-line chemotherapy drugs Alimta and cisplatin, both commonly used therapies for mesothelioma.

Recently, the company also announced that TroVax, a therapeutic cancer vaccine that stimulates an anti-cancer immune response, received approval from the U.S. Food and Drug Administration to start Phase II of a study of the drug for use against hormone refractory prostate cancer. This cancer is a form of the disease that develops when hormone therapy fails to stop its growth.

Within the North Shore-LIJ Health System, a study done by the North Shore University Hospital and LIJ Medical Center's Departments of Radiation Medicine and Urology determined that age doesn't make a difference in long-term treatment for prostate cancer. The findings were published in The Journal of Urology.